0
Deep & Emerging Tech·April 18, 2026·1 min read

Three gene therapy pioneers just won the Breakthrough Prize. This is their story

Share

Gene therapy just got another layer of establishment validation — that pulls more capital, talent, and regulators toward one-off, high-ASP cures instead of chronic-care drugs. If you're building in biotech tooling or data, assume more demand for platforms that compress design, trial, and manufacturing cycles for bespoke therapies.

Deep & Emerging Tech

Binance and Bitget to probe a rally in RaveDAO's RAVE token, which surged 4,500% in a week, after ZachXBT alleged RAVE insiders engineered a large short squeeze (Francisco Rodrigues/CoinDesk)

A token where 90% of supply sits in three wallets and still trades on major venues is a reminder: centralized exchanges are now de facto market-structure regulators. If your business touches liquid tokens, assume exchange-level surveillance and intervention risk is part of your operating environment, not an edge case.